Veletri

What it is used for

VELETRI is indicated for the long-term treatment, via continuous intravenous infusion, in WHO functional class III or class IV patients with:, Idiopathic pulmonary arterial hypertension, Familial pulmonary arterial hypertension, Pulmonary arterial hypertension associated with the scleroderma spectrum of diseases

How to take it

The way to take this medicine is: Intravenous. This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.

Store below 25 degrees Celsius
Do not Freeze
Protect from Light
Shelf lifetime is 36 Months.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.

Reporting side effects

You can help ensure medicines are safe by reporting the side effects you experience.

You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems

How to take it

The way to take this medicine is: Intravenous. This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.

Store below 25 degrees Celsius
Do not Freeze
Protect from Light
Shelf lifetime is 36 Months.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.

Pregnant or planning a pregnancy?

For the active ingredient epoprostenol

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Do I need a prescription?

This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.

Visual appearance

white to off-white lyophilised cake or powder, which on reconstitution is free from visible particles

Is this medicine subsidised?

This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on March 1, 2020. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.